Aptevo Therapeutics Announces Publication of Phase 2 Clinical Data for Otlertuzumab

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/14/2026

1. ORCL
2. NVDA
3. SPY
4. USO
5. SRRK
6. CGEM
7. DFTX
8. AZN
9. SATL
10. LYNX

Go back to Aptevo Therapeutics Announces Publication of Phase 2 Clinical Data for Otlertuzumab
(NASDAQ: APVO) Delayed: 1.85 +0.03 (1.65%)
Previous Close $1.82    52 Week High $4.33 
Open $1.85    52 Week Low $1.80 
Day High $1.90    P/E N/A 
Day Low $1.84    EPS $0.00 
Volume 37,074